Literature DB >> 16413601

Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy.

Cheng-Jeng Tai, Horng-Yuan Lo, Chung-Huei Hsu, Chen-Jei Tai, Wei-Min Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16413601     DOI： 10.1016/j.ygyno.2005.11.043

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  2 in total

1.  Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Authors:  Jason A Wilken; Kristy T Webster; Nita J Maihle
Journal:  J Ovarian Res       Date:  2010-03-27       Impact factor: 4.234

2.  Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer.

Authors:  Thore Hillig; Jørgen Thode; Marie F Breinholt; Maria-Benedicte Franzmann; Carsten Pedersen; Flemming Lund; Henrik Mygind; György Sölétormos; Martin Rudnicki
Journal:  APMIS       Date:  2012-06-26       Impact factor: 3.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.